Positive Opinion for CSD500

RNS Number : 4719N

Futura Medical PLC

09 September 2013

 



For immediate release

9 September 2013

 

 

Futura Medical plc

("Futura" or the "Company")

Positive Opinion for CSD500

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that its novel condom, CSD500, has received a positive opinion from the relevant Notified Body on all aspects of the CSD500 regulatory dossier submitted earlier in the year.  It is expected that the CE mark certificate will be awarded later this month, authorising the product for marketing throughout Europe.

CSD500 is clinically proven to produce a firmer erection and increase penile size in healthy men whilst wearing a condom during sexual intercourse and to give women a longer lasting sexual experience.

The award of the CE mark is a key step towards the launch of CSD500 in Europe. As announced on 2 April 2013, the rights to manufacture, market and distribute CSD500 in North America and a number of key European territories have been licensed to Church & Dwight Co Inc, the major US consumer products group whose brands include Trojan® condoms.

James Barder, Futura's Chief Executive, commented: "We are delighted to confirm that we have received a positive opinion on all aspects of the regulatory dossier for the CE marking of  our highly innovative condom, CSD500. We expect the CE mark certificate to be awarded to us later this month and are very excited to be moving close to the launch of the product in Europe."

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited
Juliet Thompson / Christopher Golden	Tel:[phone]
For media enquiries please contact:
Buchanan Communications
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

MSCEDLFBXKFBBBL